Epithelial Ovarian Cancer Clinical Trials in Cleveland, Ohio

4 studies are recruiting for epithelial ovarian cancer in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland, Ohio

   Locations

   70 in total

   Run by

   AbbVie

   See if you can join NCT06890338 on ClinicalTrials.gov

2. Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

   The goal of this clinical trial is to see if timed fasting (periods of time that you don't eat) in participants who are receiving chemotherapy prior to surgery is achievable, safe and can improve quality of life, symptoms and outcomes (results) compared to participants who receive standard dietary …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Department of Subspecialty Care for Women's Health Women's Health; Division of Gynecologic Oncology, Case Comprehensive Cancer Center, Cleveland, Ohio

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT06386887 on ClinicalTrials.gov

3. Study of AVZO-021 in Patients With Advanced Solid Tumors

   This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University Hospitals Cleveland Medical Center, Cleveland, Ohio

   Locations

   13 in total

   Run by

   Avenzo Therapeutics, Inc.

   See if you can join NCT05867251 on ClinicalTrials.gov

4. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

   The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cleveland Clinic, Cleveland, Ohio

   Locations

   20 in total

   Run by

   Bicara Therapeutics

   See if you can join NCT04429542 on ClinicalTrials.gov